How Oxymetholone (Anadrol) Affects ALT

Oxymetholone (Anadrol, A50) is a 17-alpha-alkylated oral steroid with exceptionally high hepatotoxic potential:

1. Intense first-pass liver exposure: Oxymetholone is used at much higher absolute doses than most other oral steroids (50-150 mg/day vs. 20-50 mg for Dianabol). This means the liver processes a significantly higher milligram load per pass.
2. Cholestatic injury: Like all C17-aa steroids, oxymetholone impairs bile salt export pump (BSEP) function, causing intrahepatic cholestasis. However, the severity of cholestasis with oxymetholone is greater due to the higher doses used.
3. Hepatocellular damage: Direct damage to hepatocyte membranes releases ALT and AST into the bloodstream. Oxymetholone causes more pronounced hepatocellular necrosis than milder oral steroids.
4. Peliosis hepatis risk: Prolonged use of oxymetholone at high doses has been associated with peliosis hepatis, a rare condition where blood-filled cystic spaces develop within the liver. This can lead to liver rupture and life-threatening haemorrhage.
5. Hepatic adenoma/carcinoma: Case reports link chronic oxymetholone use (months to years, primarily in medical settings) to hepatic tumours, though this risk is primarily associated with prolonged therapeutic use in anaemia patients.

Moderate doses (50 mg/day):

• ALT typically rises 3-8x ULN (120-320+ U/L)
• AST rises proportionally
• GGT and ALP commonly elevated, indicating cholestatic component
• Bilirubin may rise; subclinical jaundice is not uncommon

High doses (100-150 mg/day):

• ALT can reach 5-20x ULN (200-800+ U/L)
• Mixed hepatocellular and cholestatic pattern is typical
• Bilirubin elevation becomes more common and may be visible (yellow skin/eyes)
• Some users report dark urine and pale stools

Timeline: ALT elevation begins within the first week and escalates rapidly. Peak values are often seen at weeks 3-5. The rapidity and magnitude of the rise distinguishes oxymetholone from milder oral steroids.

Important: Individual variation is significant. Some users tolerate 50 mg/day with only moderate enzyme elevation, while others show dramatic rises at the same dose. Genetic differences in hepatic metabolism (CYP3A4, UGT enzymes) account for much of this variability.

Pre-cycle: Comprehensive liver panel (ALT, AST, GGT, ALP, total and direct bilirubin, albumin) is mandatory. Do not use oxymetholone if baseline liver enzymes are elevated.

On cycle: Check liver enzymes at week 2 and again at week 4. Oxymetholone escalates liver stress faster than most orals, so earlier monitoring is important.

Post-cycle: Recheck at 2 weeks and 6 weeks post-discontinuation.

Immediate cessation required if:

• ALT exceeds 10x ULN (above 400 U/L)
• Bilirubin exceeds 2x ULN
• Any clinical signs of jaundice appear
• Right upper quadrant pain or abdominal distension
• Unexplained bleeding or bruising (may indicate impaired hepatic synthesis of clotting factors)

Imaging: If liver enzymes remain significantly elevated 6+ weeks after cessation, an abdominal ultrasound should be considered to rule out peliosis hepatis or hepatic mass.

Liver support (essential, not optional with Anadrol):

• TUDCA 1000-1500 mg/day (higher dose than for milder orals due to greater cholestatic stress)
• NAC 1200 mg/day
• Milk thistle 600-1000 mg/day
• Consider adding injectable glutathione or IV NAC if available

Cycle design:

• Limit oxymetholone cycles to 4 weeks maximum; 6 weeks is the absolute ceiling
• Never stack with another C17-aa oral steroid
• Use the minimum effective dose; many users find 50 mg/day sufficient, though 100 mg is commonly used
• Allow 8-12 weeks of complete liver recovery before any subsequent oral steroid cycle

Risk reduction:

• Complete alcohol avoidance during the cycle and for 4 weeks after
• Avoid acetaminophen/paracetamol, NSAIDs, and any other hepatotoxic substances
• Stay well-hydrated to support bile flow
• High-protein, moderate-fat diet with emphasis on liver-supportive foods

If enzymes are severely elevated (above 10x ULN):

• Discontinue immediately
• Continue TUDCA and NAC at maximum doses
• Medical evaluation is recommended; severe elevations may warrant monitoring for hepatic synthetic function (INR, albumin)
• Recovery typically occurs within 4-8 weeks but can take longer with severe damage